

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-15 (canceled)

Claim 16. (new): A method for the administration of therapeutic amount of a growth factor protein formulation in the treatment of coronary artery disease comprising the step of delivering the protein formulation by inhalation therapy.

Claim 17. (new): The method of claim 16 wherein the growth factor protein formulation is selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof.

Claim 18. (new): The method of claim 16 wherein the growth factor protein formulation is selected from the group consisting of FGF-1, FGF-2 and mixtures thereof.

Claim 19. (new): The method of claim 16 wherein the growth factor protein formulation consists of VEGF.

Claim 20. (new): The method of claim 16 wherein the growth factor protein formulation is a dry powder formulation.

Claim 21. (new): The method of claim 16 wherein the growth factor protein formulation is a liquid aerosol formulation

Claim 22. (new): The method of claim 16, wherein the acute symptoms of coronary artery disease are brought on by reperfusion injury.

Claim 23. (new): The method of claim 22, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.

Claim 24. (new): A method for the administration of therapeutic amount of a growth factor protein formulation selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof, in the treatment of coronary artery disease comprising the step of delivering the protein formulation by inhalation therapy.

Claim 25. (new): The method of claim 24 wherein the growth factor protein is selected from the group consisting of FGF-1, FGF-2 and mixtures thereof.

Claim 26. (new): The method of claim 24 wherein the growth factor protein consists of VEGF.

Claim 27. (new): The method of claim 24 wherein the growth factor protein formulation is a dry powder formulation.

Claim 28. (new): The method of claim 24 wherein the growth factor protein formulation is a liquid aerosol formulation

Claim 29. (new): The method of claim 24, wherein the acute symptoms of coronary artery disease are brought on by reperfusion injury.

Claim 30. (new): The method of claim 29, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.